$5.25
2.34% yesterday
Nasdaq, Oct 01, 10:00 pm CET
ISIN
US15117N5032
Symbol
IMNN

Celsion Corporation Stock price

$5.25
-0.68 11.47% 1M
-8.51 61.85% 6M
-7.14 57.63% YTD
-8.58 62.03% 1Y
-16.66 76.04% 3Y
-135.17 96.26% 5Y
-4,514.32 99.88% 10Y
-66,555.62 99.99% 20Y
Nasdaq, Closing price Wed, Oct 01 2025
+0.12 2.34%
ISIN
US15117N5032
Symbol
IMNN
Industry

Key metrics

Basic
Market capitalization
$13.2m
Enterprise Value
$8.5m
Net debt
positive
Cash
$4.7m
Shares outstanding
2.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
5.0
Financial Health
Equity Ratio
43.7%
Return on Equity
-447.7%
ROCE
-461.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-15.3m | -
EBIT
$-16.0m | $-24.0m
Net Income
$-15.8m | $-21.4m
Free Cash Flow
$-15.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
22.0% | -
EBIT
19.5% | -26.2%
Net Income
12.9% | -12.6%
Free Cash Flow
19.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-10.7
FCF per Share
$-7.6
Short interest
3.6%
Employees
25
Rev per Employee
$0.0
Show more

Is Celsion Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Celsion Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Celsion Corporation forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Celsion Corporation forecast:

Buy
80%
Hold
20%

Financial data from Celsion Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.10 7.10
14% 14%
-
- Research and Development Expense 8.92 8.92
23% 23%
-
-15 -15
22% 22%
-
- Depreciation and Amortization 0.72 0.72
157% 157%
-
EBIT (Operating Income) EBIT -16 -16
19% 19%
-
Net Profit -16 -16
13% 13%
-

In millions USD.

Don't miss a Thing! We will send you all news about Celsion Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Celsion Corporation Stock News

Neutral
GlobeNewsWire
10 days ago
Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key anti-cancer immune cytokines post-treatment
Neutral
GlobeNewsWire
13 days ago
OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated LAWRENCEVILLE, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that new translational data from the Phase 2 OVATION 2 Study of IMNN-001, its investigational therapy for the...
Neutral
GlobeNewsWire
about one month ago
LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market following confirmation from the Nasdaq Hearings Panel. As a result, IMUNON common ...
More Celsion Corporation News

Company Profile

Celsion Corp . is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Head office United States
CEO Stacy Lindborg
Employees 25
Founded 1982
Website imunon.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today